Clinical trial
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung…
NCT00056147 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00056147 |
|---|---|
| Title | Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease |
| Official title | Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | denufosol tetrasodium (INS37217) |
| Enrollment | 90 |
| Start date | Apr 1, 2003 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Mar 7, 2003 |
| Last update posted | Jan 29, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: